This article is more than 5 years old. Information may no longer be current.
Viberzi for IBS-D now available in US
Click Here to Manage Email Alerts
Allergan today announced the availability of Viberzi, its first-in-class, twice-daily oral treatment for adults with diarrhea-predominant irritable bowel syndrome in the U.S.
Viberzi (eluxadoline, Allergan), is an orally active compound with mixed opioid receptor activity. “It is a mu receptor agonist, a delta receptor agonist and a kappa receptor agonist,” according to a press release.
“We are excited about the launch of Viberzi, which addresses an unmet need among IBS-D patients seeking a treatment to manage their symptoms proactively,” William Meury, president and executive vice president of branded pharma at Allergan, said in a press release. “This introduction reaffirms Allergan’s commitment to providing a new treatment option that serves to help gastroenterologists reach better outcomes for their patients.”
The FDA approval of eluxadoline in May followed results from two clinical trials demonstrating maintained relief of core IBS-D symptoms, including diarrhea and abdominal pain, according to the press release. The DEA designated eluxadoline as a Schedule IV drug with “low potential for abuse and low risk of dependence” on November 12.
Disclosure: Meury reports he is an employee of Allergan.